Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease

Award Number: UH3NS127943
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease - The goal of the proposed project is to evaluate the potential of and develop HBI-201, a novel oral formulation of nitrous oxide (N2O), that enables the home use of N2O to treat pain associated with Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease (SCD). The analgesic properties of N2O are well known, and N2O is an FDA- designated medical gas that is used for its analgesic, among other, properties. Importantly, current analgesic uses of N2O using inhaled gas include pain from SCD VOC in the emergency department (ED) in France, as well as in obstetric labor, acutely painful procedures such as fracture reduction, and in the management of the pain of ureteric colic. As a widely used, approved drug in the US, EU, and other geographies, the safety, tolerability, and efficacy of inhaled N2O (iN2O) has been demonstrated. However, barriers to home dosing of iN2O have prevented the development of an N2O therapeutic for home treatment of SCD VOC pain. Inhaled N2O gas is the approved modality for N2O. However, inhaled N2O is not a viable therapeutic option for home use due to poor dosing control, potential inhalation equipment issues and variability in patient ventilation and pulmonary absorption, the risk of inadvertent exposure due to leaking or incorrectly operated compressed gas cylinders, and patient resistance to gas therapies due to issues with mask and cannula use. HBI-201, a novel oral N2O drug product, enables home use of N2O in SCD and is being developed for the treatment of pain associated with VOCs in SCD. The administration of a defined dose of N2O delivered by oral administration of HBI-201 enables the further development of N2O as a therapeutic for home use while obviating the problems associated with iN2O. In this multi-PI application, we combine the expertise of the Simone and Belcher laboratories with Hillhurst’s experienced team and innovative technology and propose to build on compelling data to develop HBI-201 as a treatment for SCD VOC pain.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	HILLHURST BIOPHARMACEUTICALS, INC.	2029 N VERDUGO RD	GLENDALE	CA	91208	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	2	8/25/2026	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = -$132,384 )
2025	2024	HILLHURST BIOPHARMACEUTICALS, INC.	2029 N VERDUGO RD	GLENDALE	CA	91208	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	2	1/17/2025	EXTENSION WITH OR WITHOUT FUNDS	$0
2025	2024	HILLHURST BIOPHARMACEUTICALS, INC.	2029 N VERDUGO RD	GLENDALE	CA	91208	LOS ANGELES	USA	Drug Use and Addiction Research Programs	001	2	4/11/2025	EXTENSION WITH OR WITHOUT FUNDS	-$132,384
														Subtotal = -$132,384

Issue Date FY: 2024 ( Subtotal = $860,495 )
2024	2024	HILLHURST BIOPHARMACEUTICALS, INC.	2029 N VERDUGO RD	GLENDALE	CA	91208	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	2	9/9/2024	EXTENSION WITH OR WITHOUT FUNDS	$860,495
														Subtotal = $860,495

Grand Total All Awards = $728,111

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease

Award Number: UH3NS127943

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer